Your browser doesn't support javascript.
Remdesivir for COVID-19 in Europe: will it provide value for money?
Dal-Ré, Rafael; Banzi, Rita; Georgin-Lavialle, Sophie; Porcher, Raphaël; Sofat, Reecha; Zeitlinger, Markus; Rosendaal, Frits R.
  • Dal-Ré R; Epidemiology Unit, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid, Madrid, Spain. Electronic address: rafael.dalre@quironsalud.es.
  • Banzi R; Center for Health Regulatory Policies, Istituto di Ricerche Farmacologiche Mario Negri-IRCCS, Milan, Italy.
  • Georgin-Lavialle S; Sorbonne University, Internal Medicine Department, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
  • Porcher R; Université de Paris, Centre of Research in Epidemiology and Statistics (CRESS-UMR1153), Institut National de la Santé et de la Recherche Médicale, Paris, France.
  • Sofat R; Centre for Clinical Pharmacology, Institute of Health Informatics, University College London, London, UK.
  • Zeitlinger M; Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
  • Rosendaal FR; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands.
Lancet Respir Med ; 9(2): 127-128, 2021 02.
Article in English | MEDLINE | ID: covidwho-1199183
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Adenosine Monophosphate / Alanine / COVID-19 Drug Treatment Limits: Humans Country/Region as subject: Europa Language: English Journal: Lancet Respir Med Year: 2021 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Adenosine Monophosphate / Alanine / COVID-19 Drug Treatment Limits: Humans Country/Region as subject: Europa Language: English Journal: Lancet Respir Med Year: 2021 Document Type: Article